Characterization of anti-natalizumab antibodies in multiple sclerosis patients

Multiple Sclerosis Journal

Volumn 19, Issue 6, 2013, Pages 757-764

  Lundkvist, M ^a   Engdahl, E ^a   Holmen C ^a   Moverare R ^b,c   Olsson, T ^a   Hillert, J ^a   Fogdell Hahn, A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Thermo Fisher Scientific   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anti drug antibody; multiple sclerosis; natalizumab

Indexed keywords

DRUG ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; NATALIZUMAB; NATALIZUMAB ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SCREENING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; PREDICTION; RELAPSE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; AGED; BLOOD; IMMUNOLOGY; MIDDLE AGED; PREDICTIVE VALUE; SEROLOGY; SWEDEN; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; SEROLOGIC TESTS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877633406     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512462920     Document Type: Article

References (27)

1. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
2. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
3. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011 ; 17: 708-719
4. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009 ; 256: 405-415
5. Piehl F, Holmen C, Hillert J, et al. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study. Neurol Sci. 2011 ; 31: 289-293
6. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
7. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
8. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007 ; 28: 482-490
9. Porter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001 ; 90: 1-11
10. Leger OJ, Yednock TA, Tanner L, et al. Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 1997 ; 8: 3-16
11. Schellekens H. The immunogenicity of therapeutic proteins. Discov Med. 2010 ; 9: 560-564
12. Sorensen PS, Jensen PE, Haghikia A, et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler. 2011 ; 17: 1074-1078
13. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403
14. Krumbholz M, Pellkofer H, Gold R, et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007 ; 64: 1331-1333
15. Oliver B, Fernandez O, Orpez T, et al. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months. Mult Scler. 2011 ; 17: 368-371
16. Tatarewicz S, Miller JM, Swanson SJ, et al. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods. 2010 ; 357: 10-16
17. Jones AM, Honour JW. Unusual results from immunoassays and the role of the clinical endocrinologist. Clin Endocrinol (Oxf). 2006 ; 64: 234-244
18. Rispens T, de Vrieze H, de Groot E, et al. Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing. J Immunol Methods. 2012 ; 375: 93-99
19. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008 ; 358: 1109-1117
20. Jensen PE, Koch-Henriksen N, Sellebjerg F, et al. Prediction of antibody persistency from antibody titres to natalizumab. Mult Scler. :
21. van Schouwenburg PA, Krieckaert CL, Nurmohamed M, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol. :
22. van Helden PM, van den, Berg HM, Gouw SC, et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol. 2008 ; 142: 644-652
23. Deisenhammer F, Reindl M, Berger T. Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b. J Interferon Cytokine Res. 2001 ; 21: 167-171
24. Gibbs E, Oger J. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol. 2007 ; 190: 146-150
25. Petersen B, Bendtzen K, Koch-Henriksen N, et al. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler. 2006 ; 12: 247-252
26. Rispens T, Leeuwen A, Vennegoor A, et al. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem. 2011 ; 411: 271-276
27. van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods. 2010 ; 362: 82-88